Fact checked by Nick Blackmer Compounded versions of semaglutide, the active ingredient in weight loss drugs like Ozempic and ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Food companies’ snack offerings are suffering as economic pressures combine with demand for healthier options.

John Catsimatidis, CEO of Gristedes and D'Agostino, told FOX Business that shoppers are already seeing relief at his grocery chains.

"Relugolix CT is currently the only licensed GnRH antagonist option and is an alternative secondary medical option to GnRH agonists (eg Prostap and Zoladex) which are only licensed for up to six ...

White House press secretary Karoline Leavitt echoed those comments earlier Tuesday when she called the upheaval a “snapshot in time,” insisting the US is just ... the stock market, the numbers ...

As Dan Coatsworth, an investment analyst at AJ Bell, said: "Many people have been worried about elevated valuations among US equities for some time and looking for the catalyst for a market ...

Just 20 days ago, the US stock market was sitting at all-time highs. The US economy appeared to be growing at a solid pace. And a recession was nowhere in sight. Now, the R-word is seemingly ...